Cargando…

Identifying potential ligand molecules EGFR mediated TNBC targeting the kinase domain-identification of customized drugs through in silico methods

BACKGROUND AND PURPOSE: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer in which three hormone receptors are negative. This work aimed at identifying customized potential molecules inhibiting epidermal growth factor receptor (EGFR) by exploring variants using the pharm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vyshnavi, Hima, Namboori, Krishnan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976054/ https://www.ncbi.nlm.nih.gov/pubmed/36873279 http://dx.doi.org/10.4103/1735-5362.367792

Ejemplares similares

In Silico Analysis of the Effect of Hydrastis canadensis on Controlling Breast Cancer
por: Vyshnavi AM, Hima, et al.
Publicado: (2023)

BCAP31 drives TNBC development by modulating ligand-independent EGFR trafficking and spontaneous EGFR phosphorylation
por: Fu, Wenyan, et al.
Publicado: (2019)

Development of Hif1a Pharmacogenomic Mutation Models to Study Individual Variations in Drug Action for Tumor Hypoxia: An in Silico Approach
por: Balasubramaniam, Vaisali, et al.
Publicado: (2021)

TNBC Therapeutics Based on Combination of Fusarochromanone with EGFR Inhibitors
por: Carroll, Natalie, et al.
Publicado: (2022)

EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC
por: Liu, Yan, et al.
Publicado: (2019)

Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies
por: Aiebchun, Thitinan, et al.
Publicado: (2021)

Insulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells
por: Shin, Miyoung, et al.
Publicado: (2015)

Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR
por: Kim, Seongjae, et al.
Publicado: (2023)

In Silico Identification of Potential Phosphorylation in the Cytoplasmic Domain of Epithelial Cell Adhesion Molecule
por: Mal, Arijit, et al.
Publicado: (2020)

Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain
por: Virtanen, Anniina T., et al.
Publicado: (2023)

Chemotherapy with ceramide in TNBC
por: Legembre, Patrick, et al.
Publicado: (2015)

GHRH-antagonists in TNBC
por: Engel, Jörg B.
Publicado: (2015)

Cripto-1 in TNBC
por: Castro, Nadia P, et al.
Publicado: (2015)

Identification of Small Molecule Ligand Binding Sites On and In the ARNT PAS-B Domain
por: Xu, Xingjian, et al.
Publicado: (2023)

IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells
por: Merrouche, Yacine, et al.
Publicado: (2016)

Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34
por: Altwegg, Kristin A., et al.
Publicado: (2023)

The Landscape of Targeted Therapies in TNBC
por: Vagia, Elena, et al.
Publicado: (2020)

Identification of Immune-Related Risk Characteristics and Prognostic Value of Immunophenotyping in TNBC
por: Yi, Jiarong, et al.
Publicado: (2021)

Neural Functions Play Different Roles in Triple Negative Breast Cancer (TNBC) and non-TNBC
por: Tan, Renbo, et al.
Publicado: (2020)

Selected ideal natural ligand against TNBC by inhibiting CDC20, using bioinformatics and molecular biology
por: Liu, Naimeng, et al.
Publicado: (2021)

The Evaluation of Cytotoxic Properties from CCB-2 Sugar Complexes Against TNBC and Non-TNBC Cells
por: Jenie, Riris Istighfari, et al.
Publicado: (2021)

Quantitative Analysis of Ligand-EGFR Interactions: A Platform for Screening Targeting Molecules
por: Kuo, Wei-Ting, et al.
Publicado: (2015)

Development of new in silico methods to identify ligands for orphan GPCR
por: Weill, Nathanael, et al.
Publicado: (2008)

Fast custom wavelet analysis technique for single molecule detection and identification
por: Ganjalizadeh, Vahid, et al.
Publicado: (2022)

TNBC invasion: downstream of STAT3
por: Jackson, James G., et al.
Publicado: (2017)

Repurposing Drugs by In Silico Methods to Target BCR Kinase Domain in Chronic Myeloid Leukemia
por: Natarajan, Aparna, et al.
Publicado: (2019)

Correction: Quantitative Analysis of Ligand-EGFR Interactions: A Platform for Screening Targeting Molecules
por: Kuo, Wei-Ting, et al.
Publicado: (2015)

Epidermal growth factor receptor (EGFR) gene alteration and protein overexpression in Malaysian triple-negative breast cancer (TNBC) cohort
por: Zakaria, Zubaidah, et al.
Publicado: (2019)

In Silico Identification of Tripeptides as Lead Compounds for the Design of KOR Ligands
por: Stefanucci, Azzurra, et al.
Publicado: (2021)

Identification of Activating Mutations in the Transmembrane and Extracellular Domains of EGFR
por: Wagner, Anja, et al.
Publicado: (2022)

In Silico Investigation of Potential Src Kinase Ligands from Traditional Chinese Medicine
por: Tou, Weng Ieong, et al.
Publicado: (2012)

Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC
por: Wang, Jinguang, et al.
Publicado: (2018)

Identification of novel α7 nicotinic receptor ligands by in silico screening against the crystal structure of a chimeric α7 receptor ligand binding domain
por: Akdemir, Atilla, et al.
Publicado: (2012)

The identification of a TNBC liver metastasis gene signature by sequential CTC‐xenograft modeling
por: Vishnoi, Monika, et al.
Publicado: (2019)

The Potential of PSMA as a Vascular Target in TNBC
por: Heesch, Amelie, et al.
Publicado: (2023)

Aptamer-Based Strategies to Boost Immunotherapy in TNBC
por: Agnello, Lisa, et al.
Publicado: (2023)

Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology
por: Chaudhuri, Aiswarya, et al.
Publicado: (2023)

Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer
por: Lee, Chaelin, et al.
Publicado: (2022)

Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro
por: Choi, Hoon Sik, et al.
Publicado: (2021)

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
por: Hirokawa, Esuteru, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u8i4kgqje498h9ca4c0qrgju7k